A Phase 1, Randomized, 3-Period, Open Label, Single Dose, Cross Over Study To Evaluate The Pharmacokinetics And Safety Of Two Controlled Release Formulations Of CP-690,550.
Phase of Trial: Phase I
Latest Information Update: 13 Sep 2010
At a glance
- Drugs Tofacitinib (Primary)
- Indications Ankylosing spondylitis; Crohn's disease; Plaque psoriasis; Psoriatic arthritis; Renal transplant rejection; Rheumatoid arthritis; Ulcerative colitis
- Focus Pharmacokinetics
- 13 Sep 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
- 13 Sep 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 04 Sep 2010 New trial record